[go: up one dir, main page]

MY182591A - Compositions for use in treating eye disorders using dipyridamole - Google Patents

Compositions for use in treating eye disorders using dipyridamole

Info

Publication number
MY182591A
MY182591A MYPI2015002196A MYPI2015002196A MY182591A MY 182591 A MY182591 A MY 182591A MY PI2015002196 A MYPI2015002196 A MY PI2015002196A MY PI2015002196 A MYPI2015002196 A MY PI2015002196A MY 182591 A MY182591 A MY 182591A
Authority
MY
Malaysia
Prior art keywords
dipyridamole
compositions
eye disorders
treating eye
topically
Prior art date
Application number
MYPI2015002196A
Inventor
Moshe Rogosnitzky
Original Assignee
Remedeye Inc
O D Ocular Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedeye Inc, O D Ocular Discovery Ltd filed Critical Remedeye Inc
Publication of MY182591A publication Critical patent/MY182591A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention discloses compositions for use in treating eye disorders, the compositions including an effective amount of a topically-administered dipyridamole. Preferably, the topically- administered dipyridamole is formulated as a solution. Preferably, the topically-administered dipyridamole is at least one agent selected from the group consisting of: dipyridamole, and a pharmaceutically-acceptable salt thereof. Preferably, the effective amount corresponds to a concentration of at least about 10-5 molarity. Preferably, the effective amount is based on a treatment administration of at least once every other day.
MYPI2015002196A 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole MY182591A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL225179A IL225179A (en) 2013-03-12 2013-03-12 Compositions for use in treating eye disorders using dipyridamole
PCT/IB2014/059645 WO2014141079A1 (en) 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole

Publications (1)

Publication Number Publication Date
MY182591A true MY182591A (en) 2021-01-26

Family

ID=48916407

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015002196A MY182591A (en) 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole

Country Status (14)

Country Link
EP (1) EP2968328A4 (en)
JP (1) JP6820658B2 (en)
KR (2) KR20210010638A (en)
CN (1) CN105188702B (en)
AU (1) AU2014229371B2 (en)
BR (1) BR112015022084A2 (en)
CA (1) CA2905594A1 (en)
CL (1) CL2015002627A1 (en)
EA (1) EA035966B1 (en)
IL (1) IL225179A (en)
MX (1) MX378190B (en)
MY (1) MY182591A (en)
SG (2) SG11201507092QA (en)
WO (1) WO2014141079A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016119701A1 (en) * 2015-01-28 2016-08-04 Realinn Life Science Limited COMPOUNDS FOR ENHANCING PPARγ EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
WO2021001805A1 (en) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations and their methods of preparation
WO2021001806A1 (en) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations with reduced impurities
WO2024125322A1 (en) * 2022-12-16 2024-06-20 智泽童康(广州)生物科技有限公司 Dipyridamole for preventing and treating allergic and/or inflammatory diseases and preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258084A (en) * 1994-03-17 1995-10-09 Rohto Pharmaceut Co Ltd Intracular pressure-reducing agent containing dipyridamole as essential component
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
TWI435729B (en) * 2005-11-09 2014-05-01 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
WO2010056710A1 (en) * 2008-11-11 2010-05-20 Biovista, Inc. Compositions and methods for treating eye diseases
EP2363126A1 (en) * 2010-03-04 2011-09-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition comprising as active ingredient L-carnitine in combination with hydroxykynurenine-O-beta-DL-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation

Also Published As

Publication number Publication date
EP2968328A4 (en) 2016-11-23
BR112015022084A2 (en) 2017-07-18
CN105188702A (en) 2015-12-23
SG11201507092QA (en) 2015-10-29
WO2014141079A1 (en) 2014-09-18
EA035966B1 (en) 2020-09-07
IL225179A (en) 2017-01-31
EA201591653A1 (en) 2017-05-31
SG10201706937UA (en) 2017-09-28
MX2015012716A (en) 2016-07-06
AU2014229371B2 (en) 2018-05-10
JP2016514123A (en) 2016-05-19
CN105188702B (en) 2019-03-26
CA2905594A1 (en) 2014-09-18
AU2014229371A1 (en) 2015-10-29
JP6820658B2 (en) 2021-01-27
MX378190B (en) 2025-03-10
IL225179A0 (en) 2013-06-27
KR20210010638A (en) 2021-01-27
EP2968328A1 (en) 2016-01-20
CL2015002627A1 (en) 2016-03-11
KR20150126021A (en) 2015-11-10

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2015010125A (en) Pyridazinone-amides derivatives.
MX389242B (en) COMPOUNDS FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISORDERS
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX391850B (en) COMPOUNDS FOR USE IN THE TREATMENT OR AMENDING OF HUNTINGTON'S DISEASE
EA201591743A8 (en) STIMULATORS sGC
MX2015012502A (en) Dna-pk inhibitors.
IN2015DN01156A (en)
MX368833B (en) Quinoline and quinazoline amides as modulators of sodium channels.
MX2015016983A (en) Nuclear transport modulators and uses thereof.
UA117032C2 (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma
MX2015009444A (en) Novel traps in the treatment of macular degeneration.
MX2016005668A (en) Crystalline forms of therapeutic compounds and uses thereof.
EA201591628A1 (en) DEUTERED PALBOCYCLIB
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
UA115357C2 (en) Pyridin-4-yl derivatives
MX2016016404A (en) Methods for treating pruritus.
MY182591A (en) Compositions for use in treating eye disorders using dipyridamole
EA201591434A1 (en) METHOD OF PROVIDING THE EYE NEUROPROTECTION
EA201491878A1 (en) SUBSTITUTED XANTHINE DERIVATIVES
MX366805B (en) Use of zinc coceth sulfate as an antibacterial agent against propionibacterium acnes.
MX2016014261A (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis.
NZ764041A (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis
IN2013MU01157A (en)